uniQure Q3 EPS $(1.02) Down From $(0.79) YoY
uniQure (NASDAQ:QURE) reported quarterly losses of $(1.02) per share. This is a 29.11 percent decrease over losses of $(0.79) per share from the same period last year.
Wells Fargo Maintains Equal-Weight on uniQure, Lowers Price Target to $24
Wells Fargo analyst Yanan Zhu maintains uniQure (NASDAQ:QURE) with a Equal-Weight and lowers the price target from $34 to $24.
Why Karuna Therapeutics Jumped Around 72%; Here Are 96 Biggest Movers From Yesterday
Gainers
Helbiz, Inc. (NASDAQ: HLBZ) jumped 114.6% to close at $1.61 on Monday after climbing over 27% on Friday.
Nasdaq Turns Lower; Crude Oil Rises Over 1%
U.S. stocks pared gains toward the end of trading, with the S&P 500 and the Nasdaq turning lower on Monday.
Mosaic Tumbles Around 10%, Here’s 71 Biggest Movers From Yesterday
Gainers
Fujian Blue Hat Interactive Entertainment Technology Ltd. (NASDAQ: BHAT) shares jumped 263% to $2.73 on Thursday. Blue Hat Interactive terminated its previously proposed shelf takedown offering.
UniQure Shares Are Up After Low-Dose Cohort Data From Huntington’s Gene Therapy Trial
UniQure N.V. (NASDAQ:QURE) announced safety and biomarker data from 10 patients enrolled in the low-dose cohort of the ongoing Phase 1/2…
uniQure Announces Update On Low-Dose Cohort In Phase I/II Clinical Trial Of AMT-130 Gene Therapy For The Treatment Of Huntington’s Disease
~ Treatment generally well-tolerated with no significant safety issues related to AMT-130 in treated patients through one year of follow-up ~
~ A mean reduction of 53.8% of mutant HTT (mHTT) observed in
Mizuho Comments On UniQure’s Upcoming Low-Dose Huntington’s Gene Therapy Trial Data
The much-awaited one-year data for the entire low-dose cohort for UniQure NV's (NASDAQ: QURE) AMT-130 gene therapy in Huntington's disease is expected at any time.
Analyst Ratings for uniQure
Within the last quarter, uniQure (NASDAQ:QURE) has observed the following analyst ratings: